Blackbaud Falls Short of Estimates and 4 Stocks Falling to 52-Week Lows
Abiomed (NASDAQ:ABMD) announced, at the same time as its second quarter earnings report, that on October 26th it was informed that the United States Attorney’s Office for the District of Columbia is performing an inquiry focused on the firm’s marketing and labeling of the Impella 2.5. On Wednesday, Abiomed accepted the service of a Health Insurance Portability and Accountability Act administrative subpoena linked to this investigation. According to the firm, “The subpoena seeks documents related to the Impella 2.5 and we understand the investigation focuses primarily on marketing and labeling issues. Abiomed is in the process of responding to the subpoena and intends to cooperate fully.” Shares closed down 31.33 percent on the day at $13.61, but have been traded in a 52-week range of $15.12 to $26.17.
Blackbaud (NASDAQ:BLKB) estimates its fourth quarter revenue as between $119 million and $121 million, compared to consensus of $126.3 million, along with its fiscal year 2012 adjusted earnings per share of 91 to 92 cents, with a consensus of 93 cents. Also, the company’s fiscal year 2012 revenue is forecast between $451 million and $453 million, against a consensus of $464.3 million. Comments are from Bloomberg, which cited Blackbaud’s earnings conference call. Shares closed down 4.21 percent on the day at $22.77, and have traded in a 52-week range of $22.63 to $34.00.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Exelon Corporation (NYSE:EXC) posts its third quarter adjusted earnings per share of 77 cents, with a consensus of 72 cents. Shares closed down 6.15 percent on the day at $33.58, having been traded in a 52-week range of $34.54 to $45.45.
GSE Holding (NYSE:GSE) reports its third quarter adjusted earnings per share of 27 cents, compared to consensus of 35 cents. Shares closed down 6.53 percent on the day at $7.44, but have traded in a 52-week range of $8.05 to $13.98.
Panasonic Corporation (NYSE:PC) says that it will cease the sales of the Eluga phone in Europe, while it endeavors to streamline unprofitable operations, according to the Wall Street Journal. This comes less than one year after the company announced it would release a smartphone outside of Japan for the first time. For now, Panasonic will concentrate on more competitive divisions, among which include home appliances and rechargeable batteries. Shares closed down 5.42 percent on the day at $5.23, having been traded in a 52-week range of $6.04 to $11.00.
Don’t Miss: Can Apple Get Its Groove Back?